High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: An exploratory analysis of the JUPITER trial

Jessica M. Peña, Jean MacFadyen, Robert J. Glynn, Paul M. Ridker

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Aims Increasing evidence supports a role for inflammation in promoting atrial fibrillation (AF) and statins have anti-inflammatory effects that may be relevant for the prevention of AF. However, studies of statin therapy and incident AF have yielded mixed results and not focused on individuals with an underlying pro-inflammatory response. We studied whether high-sensitivity C-reactive protein is associated with incident AF and whether treatment with rosuvastatin is associated with a lower incidence of AF compared with placebo.Methods and resultsWe randomized men and women with LDL cholesterol <130 mg/dL and high-sensitivity C-reactive protein <2 mg/L to receive either rosuvastatin 20 mg daily or placebo. Atrial fibrillation was determined from treatment-blind adverse event reports. Among 17 120 participants without prior history of arrhythmia, each increasing tertile of baseline high-sensitivity C-reactive protein was associated with a 36 increase in the risk of developing AF (95 CI: 1.161.60; P-trend < 0.01). Allocation to rosuvastatin when compared with placebo was associated with a 27 reduction in the relative risk of developing AF during the trial period; specifically, AF was reported among 138 participants in the placebo group and 100 in the rosuvastatin group (incidence rate 0.78 vs. 0.56/100 person-years, HR: 0.73, 95 CI: 0.560.94, P = 0.01). The exclusion of participants who developed a major cardiovascular event prior to the report of AF yielded similar results.ConclusionWithin the JUPITER trial cohort of individuals selected for underlying inflammation, increasing levels of high-sensitivity C-reactive protein were associated with an increased risk of incident AF and random allocation to rosuvastatin significantly reduced that risk.

Original languageEnglish (US)
Pages (from-to)531-537
Number of pages7
JournalEuropean Heart Journal
Volume33
Issue number4
DOIs
StatePublished - Feb 2012
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
C-Reactive Protein
Atrial Fibrillation
Placebos
Therapeutics
Inflammation
Incidence
Random Allocation
LDL Cholesterol
Cardiac Arrhythmias
Anti-Inflammatory Agents
Rosuvastatin Calcium

Keywords

  • Atrial fibrillation
  • C-reactive protein
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation : An exploratory analysis of the JUPITER trial. / Peña, Jessica M.; MacFadyen, Jean; Glynn, Robert J.; Ridker, Paul M.

In: European Heart Journal, Vol. 33, No. 4, 02.2012, p. 531-537.

Research output: Contribution to journalArticle

Peña, Jessica M. ; MacFadyen, Jean ; Glynn, Robert J. ; Ridker, Paul M. / High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation : An exploratory analysis of the JUPITER trial. In: European Heart Journal. 2012 ; Vol. 33, No. 4. pp. 531-537.
@article{0072722736654a6ea8e4657732e0e011,
title = "High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: An exploratory analysis of the JUPITER trial",
abstract = "Aims Increasing evidence supports a role for inflammation in promoting atrial fibrillation (AF) and statins have anti-inflammatory effects that may be relevant for the prevention of AF. However, studies of statin therapy and incident AF have yielded mixed results and not focused on individuals with an underlying pro-inflammatory response. We studied whether high-sensitivity C-reactive protein is associated with incident AF and whether treatment with rosuvastatin is associated with a lower incidence of AF compared with placebo.Methods and resultsWe randomized men and women with LDL cholesterol <130 mg/dL and high-sensitivity C-reactive protein <2 mg/L to receive either rosuvastatin 20 mg daily or placebo. Atrial fibrillation was determined from treatment-blind adverse event reports. Among 17 120 participants without prior history of arrhythmia, each increasing tertile of baseline high-sensitivity C-reactive protein was associated with a 36 increase in the risk of developing AF (95 CI: 1.161.60; P-trend < 0.01). Allocation to rosuvastatin when compared with placebo was associated with a 27 reduction in the relative risk of developing AF during the trial period; specifically, AF was reported among 138 participants in the placebo group and 100 in the rosuvastatin group (incidence rate 0.78 vs. 0.56/100 person-years, HR: 0.73, 95 CI: 0.560.94, P = 0.01). The exclusion of participants who developed a major cardiovascular event prior to the report of AF yielded similar results.ConclusionWithin the JUPITER trial cohort of individuals selected for underlying inflammation, increasing levels of high-sensitivity C-reactive protein were associated with an increased risk of incident AF and random allocation to rosuvastatin significantly reduced that risk.",
keywords = "Atrial fibrillation, C-reactive protein, Statins",
author = "Pe{\~n}a, {Jessica M.} and Jean MacFadyen and Glynn, {Robert J.} and Ridker, {Paul M.}",
year = "2012",
month = "2",
doi = "10.1093/eurheartj/ehr460",
language = "English (US)",
volume = "33",
pages = "531--537",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation

T2 - An exploratory analysis of the JUPITER trial

AU - Peña, Jessica M.

AU - MacFadyen, Jean

AU - Glynn, Robert J.

AU - Ridker, Paul M.

PY - 2012/2

Y1 - 2012/2

N2 - Aims Increasing evidence supports a role for inflammation in promoting atrial fibrillation (AF) and statins have anti-inflammatory effects that may be relevant for the prevention of AF. However, studies of statin therapy and incident AF have yielded mixed results and not focused on individuals with an underlying pro-inflammatory response. We studied whether high-sensitivity C-reactive protein is associated with incident AF and whether treatment with rosuvastatin is associated with a lower incidence of AF compared with placebo.Methods and resultsWe randomized men and women with LDL cholesterol <130 mg/dL and high-sensitivity C-reactive protein <2 mg/L to receive either rosuvastatin 20 mg daily or placebo. Atrial fibrillation was determined from treatment-blind adverse event reports. Among 17 120 participants without prior history of arrhythmia, each increasing tertile of baseline high-sensitivity C-reactive protein was associated with a 36 increase in the risk of developing AF (95 CI: 1.161.60; P-trend < 0.01). Allocation to rosuvastatin when compared with placebo was associated with a 27 reduction in the relative risk of developing AF during the trial period; specifically, AF was reported among 138 participants in the placebo group and 100 in the rosuvastatin group (incidence rate 0.78 vs. 0.56/100 person-years, HR: 0.73, 95 CI: 0.560.94, P = 0.01). The exclusion of participants who developed a major cardiovascular event prior to the report of AF yielded similar results.ConclusionWithin the JUPITER trial cohort of individuals selected for underlying inflammation, increasing levels of high-sensitivity C-reactive protein were associated with an increased risk of incident AF and random allocation to rosuvastatin significantly reduced that risk.

AB - Aims Increasing evidence supports a role for inflammation in promoting atrial fibrillation (AF) and statins have anti-inflammatory effects that may be relevant for the prevention of AF. However, studies of statin therapy and incident AF have yielded mixed results and not focused on individuals with an underlying pro-inflammatory response. We studied whether high-sensitivity C-reactive protein is associated with incident AF and whether treatment with rosuvastatin is associated with a lower incidence of AF compared with placebo.Methods and resultsWe randomized men and women with LDL cholesterol <130 mg/dL and high-sensitivity C-reactive protein <2 mg/L to receive either rosuvastatin 20 mg daily or placebo. Atrial fibrillation was determined from treatment-blind adverse event reports. Among 17 120 participants without prior history of arrhythmia, each increasing tertile of baseline high-sensitivity C-reactive protein was associated with a 36 increase in the risk of developing AF (95 CI: 1.161.60; P-trend < 0.01). Allocation to rosuvastatin when compared with placebo was associated with a 27 reduction in the relative risk of developing AF during the trial period; specifically, AF was reported among 138 participants in the placebo group and 100 in the rosuvastatin group (incidence rate 0.78 vs. 0.56/100 person-years, HR: 0.73, 95 CI: 0.560.94, P = 0.01). The exclusion of participants who developed a major cardiovascular event prior to the report of AF yielded similar results.ConclusionWithin the JUPITER trial cohort of individuals selected for underlying inflammation, increasing levels of high-sensitivity C-reactive protein were associated with an increased risk of incident AF and random allocation to rosuvastatin significantly reduced that risk.

KW - Atrial fibrillation

KW - C-reactive protein

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84857157135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857157135&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehr460

DO - 10.1093/eurheartj/ehr460

M3 - Article

C2 - 22187510

AN - SCOPUS:84857157135

VL - 33

SP - 531

EP - 537

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 4

ER -